Acquisition Completed
Amneal Pharmaceuticals acquisition of Kashiv BioSciences
US$375m consideration
Announced 22 Apr 2026
Advisers
Kashiv BioSciences
Target
- Financial adviser
- Legal adviser
- Served as an advisor in India
- Dhinal Shah Associates
Amneal Pharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Blue Raven LLP
- Fairness opinion
- Consultants
- Boston Consulting Group
(as The Boston Consulting Group)InterPharmaLink AG
- Target
- Kashiv BioSciences
- Acquirer
- Amneal Pharmaceuticals
- Target based in
- United States
- Buyer based in
- United States
- Structure
- Private sale
- Completed
- 10 Aug 2026
- Sector
- Biotech
- Tags
- Biotech, Pharma, Drug Development
In the league tables
- M&A financial advisers, 2026 to date J.P. Morgan #1 · Goldman Sachs #2
- M&A financial advisers, completed, 2026 to date J.P. Morgan #1 · Goldman Sachs #2
- M&A legal advisers, 2026 to date Simpson Thacher & Bartlett #18 · Holland & Knight #88 · Richards, Layton & Finger #124
- M&A legal advisers, completed, 2026 to date Simpson Thacher & Bartlett #10 · Holland & Knight #57 · Richards, Layton & Finger #71
- Fairness opinion providers, 2026 to date Goldman Sachs #1
Similar deals
- Eli Lilly and Company acquisition of Ventyx Biosciences Jan 2026 · US$1.2bn · Biotech
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
- Adial Pharmaceuticals acquisition of Azora Therapeutics Jun 2026 · Biotech
- Tarsus Pharmaceuticals acquisition of Alkeus Pharmaceuticals Aug 2026 · US$450m · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
Sources
- 22 Apr 2026 Press release (EX-99.1, exhibit), Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; sec.gov
- 29 Jun 2026 Definitive merger proxy statement (DEFM14A), Amneal Pharmaceuticals, Inc. sec.gov
- 10 Aug 2026 Press release (EX-99.1, exhibit), Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader sec.gov

